As Per the Research Report, the Europe Immunotherapy Drugs Market Size is valued at USD 20.33 billion in 2021 and is forecasted to reach USD 33.64 billion by 2026, growing at a CAGR of 10.6% during the forecast period 2021 to 2026.
Increasing the prevalence of cancer, contagious and autoimmune diseases is driving the European immunotherapy drugs market. Moreover, the increasing adoption of immunotherapy drugs over conventional treatment regimens is expected to expand the market growth. Also, the growing demand for monoclonal biosimilars and expedited regulatory approvals are anticipated to impact market growth positively.
In Addition, the respective death statistics from lung cancer, liver cancer, colorectal cancer, stomach cancer, and breast cancer significantly contribute to the immunotherapy drugs market. The leading chronic diseases are cancer, kidney failure, autoimmune and inflammatory diseases, and heart disease. For example, according to Versus Arthritis, estimated that more than 19.6% of people over the age of 45 in England had osteoarthritis of the knee.
The most common cancers are lung cancer, liver cancer, colorectal cancer, stomach cancer, and breast cancer, which caused 1.71 million across nations. According to the WHO, the leading cause of the total number of deaths in Europe is around 213,663 min, and 98,982 women are diagnosed with lung cancer. As a result, lung cancer is second and third most prevalent cancer in men and women. Therefore, the European immunotherapy Drugs market has been growing at a lucrative rate in recent years and will maintain the same steady pace in the projected period.
According to statistics, cancer kills about one out of every seven people. The increased incidence of cancer is due to a decline in lifestyle, including smoking and alcoholism. Therefore, the rise in the European immunotherapy medication market is primarily due to an increase in the cancer population. There are numerous treatments on the market, but immunotherapy has the benefit of being more effective and having fewer adverse effects than other medications. Furthermore, when chemotherapy and other forms of radiation treatment fail to work for melanoma patients, this therapy is beneficial, boosting the market's growth rate.
The high cost of drug treatment and the higher attrition rate in the product development cycle is hindered by the market's growth.
This research report on the Europe Immunotherapy Drugs Market has been segmented and sub-segmented into the following categories
By Drug Type:
Geographically, the European immunotherapy drugs market is expected to witness a predominant share during the forecast period. The market growth is linked to the growing demand for safer cancer therapies, the availability of advanced technology, and the introduction of favorable reimbursement policies. The major countries such as Germany, the UK, and France significantly contribute to regional market growth.
The UK immunotherapy drugs market dominated the European immunotherapy drugs market, and it is anticipated to witness the largest share during the predicted period. Similarly, France had the second-largest share in that year. The market growth in these countries was driven by a higher prevalence of cancer, growing demand for better diagnostics, favorable reimbursement policies, and implementation of initiatives.
In recent years, France immunotherapy drugs market and the UK immunotherapy drugs market have been the major contributors to the European immunotherapy drugs market because of their reputation as an ideal location for research and development. The need for immunotherapy drugs is in high demand in both regions and is expected to grow in the future.
In Europe, the Sweden immunotherapy drugs market is likely to become the fastest-growing market. However, Germany immunotherapy drugs market is expected to grow at the highest rate during the forecast period, owing to aggressive investments by major market players, increasing public health spending, and the disposable income of the population.
In Addition, the countries like Russia and Netherlands have the lowest growth compared to other regions. However, increasing cancer incidence due to smoking, lifestyle change, and excessive alcohol consumption boosts the immunotherapy drugs market in this region.
KEY MARKET PLAYERS
Top Companies leading the Europe Immunotherapy Drugs Market Profiled in the Report are Roche, Merck, Eli Lilly, Novartis, AstraZeneca, GlaxoSmithKline PLC, Amgen, Celgene, Bristol Myers Squibb, and Seattle Genetics.,
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Drug Type
5.1.1 Monoclonal Antibodies
5.1.5 Checkpoint Inhibitors
5.2 By Application
5.2.1 Blood Cancer
5.2.2 Cervical Cancer
5.2.3 Breast Cancer
5.2.5 Lung Cancer
5.2.6 Gastric Cancer
5.2.7 Prostate Cancer
6. Geographical Analysis
7. Pipeline Product Analysis
7.2 Pipeline Development Landscape
7.3 Molecular Targets in the Pipeline
7.4 Clinical Trials
7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target.
8. Strategic Analysis
8.1 PESTLE analysis
8.2 Porter’s Five analysis
8.2.1 Bargaining Power of Suppliers
8.2.2 Bargaining Power of Consumers
8.2.3 Threat of New Entrants
8.2.4 Threat of Substitute Products and Services
8.2.5 Competitive Rivalry within the Industry
9. Market Leaders' Analysis
9.1 Eli Lilly
9.1.2 Product Analysis
9.1.3 Financial analysis
9.1.4 Recent Developments
9.1.5 SWOT analysis
9.1.6 Analyst View
9.8 Bristol Myers Squibb
9.9 GlaxoSmithKline PLC
9.10 Seattle Genetics
10. Competitive Landscape
10.1 Market share analysis
10.2 Merger and Acquisition Analysis
10.3 Agreements, collaborations and Joint Ventures
10.4 New Product Launches
11. Market Outlook and Investment Opportunities
a) List of Tables
b) List of Figures